News | May 27, 2015

OctreoPharm develops novel radio-labeled somatostatin receptor antagonist peptides for neuroendocrine tumor management

Ipsen, OctreoPharm Sciences, acquisition, NET, radioactive-labeled compound

May 27, 2015 — Ipsen announced the signature of an agreement to acquire OctreoPharm Sciences, a private German life sciences company developing innovative radioactive-labeled compounds for molecular imaging diagnostics and therapeutic applications. Ipsen plans to maintain the company location and staff to ensure successful transition of know-how and expertise. The company expects to complete its acquisition once closing conditions have been cleared.

Under the terms of the agreement, which is subject to closing conditions, OctreoPharm’s shareholders are eligible to receive up to a total of approximately €50 million for the purchase of 100 percent of the company’s shares in the form of an upfront payment and downstream payments contingent upon clinical and regulatory milestones.

The transaction fits into Ipsen’s strategy to extend the scope of its portfolio in neuroendocrine tumors (NET). OctreoPharm is developing an innovative theranostic approach for the management of NET based on a somatostatin receptor antagonist peptide. The therapeutic compound is a tumor cell-selective somatostatin antagonist peptide labeled with Lutetium-177 (Lu-177) for use as ‘peptide receptor radionuclide therapy’ (PRRT) for the treatment of neuroendocrine tumors, and is currently in preclinical development. The diagnostic compound is an NET imaging tool utilizing positron emission tomography/computed tomography (PET, PET/CT), and is currently in clinical development.

The acquisition includes an agreement with Eckert and Ziegler, one of OctreoPharm’s shareholders, to provide contract manufacturing services for the radio-labeling of the therapeutic compound.

For more information: www.ipsen.com, www.octreopharm.com


Related Content

News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
News | Quality Assurance (QA)

November 25, 2023 — Mirion announced that it will debut the new Instadose VUE personal dosimeter, from its Dosimetry ...

Time November 25, 2023
arrow
News | PET-CT

November 22, 2023 — Siemens Healthineers has announced the U.S. Food and Drug Administration (FDA) clearance of the ...

Time November 22, 2023
arrow
News | Artificial Intelligence

November 21, 2023 — Heuron, a medical AI (artificial intelligence) imaging software solution company, under the ...

Time November 21, 2023
arrow
News | Information Technology

November 21, 2023 — GE HealthCare has received U.S. FDA 510(k) Clearance for the new version of Digital Expert Access ...

Time November 21, 2023
arrow
News | Radiopharmaceuticals and Tracers

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
arrow
News | Radiation Oncology

October 17, 2023 — Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and ...

Time October 17, 2023
arrow
News | Radiopharmaceuticals and Tracers

October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE) ...

Time October 11, 2023
arrow
News | Breast Imaging

October 11, 2023 — A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth ...

Time October 11, 2023
arrow
Subscribe Now